Skip to main content
SpringerLink
Log in

Pharmacokinetics of Haloperidol

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma concentration of the drug. Chemical assays such as high pressure liquid chromatography (HPLC) and gas-liquid chromatography (GLC) have good precision and sensitivity; radioimmunoassay (RIA) is generally more sensitive, but less precise and specific. Radioreceptor assay quantifies dopamine-receptor blocking activity but does not provide results comparable with those of HPLC, GLC and RIA.

Large doses of haloperidol can safely be given intravenously and intramuscularly for rapid neuroleptisation; the bioavailability of this agent administered orally ranges from 60 to 65%. However, there is large inter individual, but not intraindividual, variability in plasma haloperidol concentrations and most pharmacokinetic parameters. This interindividual variability could be partially explained by the reversible oxidation/reduction metabolic pathway of haloperidol: it is metabolised via reduction to reduced haloperidol, which is biologically inactive. Different extents of enterohepatic recycling, and ethnic differences in metabolism, could also account for the observed variability in haloperidol disposition.

Although not conclusive from different clinical studies, it appears that a plasma haloperidol concentration range of 4 µg/L to an upper limit of 20 to 25 µg/L produces therapeutic response. The role of reduced haloperidol in determining clinical response is not clear, although in some studies a high reduced haloperidol/haloperidol concentration ratio has been suggested to be associated with therapeutic failure. Measurements of red blood cell or cerebrospinal fluid haloperidol concentration have also been proposed as determinants of therapeutic response, but results from different studies are inconsistent, and do not seem to provide a significant advantage over plasma concentration monitoring. Physiological parameters such as prolactin and homovanillic acid levels have been evaluated, with the latter showing some promise that warrants further investigation.

Haloperidol decanoate can be characterised by a flip-flop pharmacokinetic model because its absorption rate constant is slower than the elimination rate constant. Its plasma concentration peaks on day 7 after intramuscular injection. The elimination half-life is about 3 weeks, and the time to steady-state is about 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abernethy DR, Greenblatt DJ, Och HR, Willis C, Miller DD, et al. Haloperidol determination in serum and cerebrospinal fluid using gas liquid chromatography with nitrogen phosphorus detection: application to pharmacokinetic studies. Journal of Chromatography 307: 194–199, 1984

    Article  PubMed  CAS  Google Scholar 

  • Altamura C, Mauri M, Cavallaro R, Colacurico F, Gorni A, et al. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidence. Progress in Neuro-psychopharmacology and Biological Psychiatry 12: 689–694, 1988

    Article  PubMed  CAS  Google Scholar 

  • Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, et al. Does carbamazepine induced reduction of plasma haloperidol levels worsen psychotic symptoms? American Journal of Psychiatry 143: 650–651, 1986

    PubMed  CAS  Google Scholar 

  • Ayd FJ. Intravenous haloperidol therapy. International Drug Therapy Newsletter 13: 20–23, 1978

    Google Scholar 

  • Ayd FJ. Intravenous haloperidol-lorazepam therapy for delirium. International Drug Therapy Newsletter 19: 33–35, 1984

    Google Scholar 

  • Baastrup PC, Hallnagel P, Sorensen R, Schou M. Adverse reactions in treatment with lithium carbonate and haloperidol. Journal of the American Medical Association 236(23): 2645–2646, 1976

    Article  PubMed  CAS  Google Scholar 

  • Balant-Georgia AE, Balant L. Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clinical Pharmacokinetics 13: 65–90, 1987

    Article  Google Scholar 

  • Beresford R, Ward A. Haloperidol decanoate, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33: 31–49, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bianchetti G, Zarifian E, Poirier-Littre MF, Morselli PL, Deniker P. Influence of route of administration of haloperidol plasma levels in psychotic patients. International Journal of Clinical Pharmacology, Therapy and Toxicology 18: 324–327, 1980

    CAS  Google Scholar 

  • Birkhimer L, Curtis JL, Jann MW. Use of carbamazepine in psychiatric disorders. Clinical Pharmacy 4: 425–434, 1985

    PubMed  CAS  Google Scholar 

  • Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 67: 17–23, 1980

    Article  PubMed  CAS  Google Scholar 

  • Browning JL, Harrington CA, Davis CM. Quantification of reduced haloperidol and haloperidol by radioimmunoassay. Journal of Immunoassay 6: 45–66, 1985

    Article  PubMed  CAS  Google Scholar 

  • Browning JL, Silverman PB, Harrington CA, Davis CM. Preliminary behavioral and pharmacologic studies on the haloperidol metabolite reduced haloperidol. Society of Neuroscience Abstracts 8: 470, 1982

    Google Scholar 

  • Chang WH, Chen TY, Lee CF, Hu WH, Yeh EK. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients. Biological Psychiatry 22: 1406–1408, 1987

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Chen TY, Lee CF, Hung JC, Hu WH, et al. Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatry Research 23: 239–244, 1988

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Jaw SS, Wu HS, Sheng H, Tsay L, et al. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs. Psychopharmacology 96: 285–288, 1988

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Lin SK, Jann MW, Lam YWF, Chen TY, et al. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biological Psychiatry 26: 239–249, 1989

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Wu HS, Tseng YT. Reduced haloperidol and haloperidol: effects of homovanillic acid in caudate and prefrontal cortex. Biological Psychiatry 22: 1369–1374, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson B, et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology 91: 410–414, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cohen BM, Babb S, Campbell A, Baldessarini RJ. Persistence of haloperidol in the brain. Archives of General Psychiatry 45: 879–880, 1988

    Article  PubMed  CAS  Google Scholar 

  • Cohen BM, Baldessarini RJ. Haloperidol levels and clinical response. American Journal of Psychiatry 138: 1513–1514, 1981

    PubMed  CAS  Google Scholar 

  • Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. Journal of the American Medical Association 230: 1283–1287, 1974

    Article  PubMed  CAS  Google Scholar 

  • Contreras S, Alexander H, Faber R, Bowden C. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia. Journal of Clinical Psychopharmacology 8(2): 95–97, 1987

    Google Scholar 

  • Creese I, Synder S. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270: 180–182, 1977

    Article  PubMed  CAS  Google Scholar 

  • Cressman WA, Bianche JR, Slotnick VB, Johnson PC, Plostnicks J. Plasma profile of haloperidol in man following intramuscular administration. European Journal of Clinical Pharmacology 7: 99–103, 1974

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clinical Pharmacokinetics 11: 36–61, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dalby MA. Antiepileptic and psychotrophic effect of carbamazepine in the treatment of psychomotor epilepsy. Epilepsia 12: 325–334, 1971

    Article  PubMed  CAS  Google Scholar 

  • Davidson M, Davis KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Archives of General Psychiatry 45: 561–563, 1988

    Article  PubMed  CAS  Google Scholar 

  • Davidson M, Giordani AB, Mohs RC, Horvath TB, Davis BM, et al. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. Archives of General Psychiatry 44: 189, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Davidson M, Losonczy MF, Mohs RC, Lesser JC, Powchik P, et al. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology 1(1): 17–23, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Deberdt R, Elens P, Berghmans W, Heykants J, Woestenborghs R, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy, efficacy, dosage schedule and plasma levels. Acta Psychiatrica Scandinavica 62: 356–363, 1980

    Article  PubMed  CAS  Google Scholar 

  • De Buck RP, Zelaschi R, Gilles C, Durdu J, Bravman H. Theoretical and practical importance of plasma levels of haloperidol: correlations with clinical and computerized EEG data. Progress in Neuro-Psychopharmacology 5: 499–502, 1981

    Article  PubMed  Google Scholar 

  • De Cuyper H, Bollen J, Van Praag HM, Verstraeten C. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. British Journal of Psychiatry 148: 560–566, 1986

    Article  PubMed  Google Scholar 

  • Donlon PT, Hopkin J, Tupin JP. Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol. American Journal of Psychiatry 136: 273–278, 1979

    PubMed  CAS  Google Scholar 

  • Dose M, Aplet S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 22: 303–310, 1987

    Article  PubMed  CAS  Google Scholar 

  • Dreyfuss J, Shaw JM, Ross RR. Fluphenazine enanthate and fluphenazine decanoate: intramuscular injections and esterification as requirements for slow-release characteristics in dogs. Journal of Pharmaceutical Sciences 65: 1310–1315, 1976

    Article  PubMed  CAS  Google Scholar 

  • Dudley DL, Rowlett DB, Loebel PJ. Emergency use of intravenous haloperidol. General Hospital Psychiatry: 240–246, 1979

    Google Scholar 

  • Dunlop SR, Shea PA, Hendrie HC. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population. Biological Psychiatry 17(8): 929–937, 1982

    PubMed  CAS  Google Scholar 

  • Ebling WF, Jusko WJ. The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits. Journal of Pharmacokinetics and Biopharmaceutics 14: 557–599, 1986

    PubMed  CAS  Google Scholar 

  • Eddington ND, Young D. Sensitive electrochemical high performance liquid chromatography assay for the simultaneous determination of haloperidol and reduced haloperidol. Journal of Pharmaceutical Sciences 77: 541–543, 1988

    Article  PubMed  CAS  Google Scholar 

  • Ereshefsky L, Saklad SR, Jann MJ, Davis CM, Richards A, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry 45 (5, Pt. 2): 50–59, 1984

    PubMed  CAS  Google Scholar 

  • Erickson SE, Hurt SW, Chang S. Haloperidol dose, plasma levels, and clinical response: a double-blind study. Psychopharmacology Bulletin 14: 15–16, 1978

    Google Scholar 

  • Fast DK, Jones BD, Kusalic M, Erickson M. Effect of carbamazepine on neuroleptic plasma levels and efficacy. American Journal of Psychiatry 143: 117–118, 1986

    PubMed  CAS  Google Scholar 

  • Ferry JJ, Wagner JG. The non-linear pharmacokinetics of prednisone and prednisolone. I. Theoretical. Biopharmaceutics and Drug Disposition 7: 91–101, 1986

    Article  CAS  Google Scholar 

  • Forsman A, Folsch G, Larsson M, Ohman R. On the metabolism of haloperidol in man. Current Therapeutic Research 21: 606–617, 1977

    CAS  Google Scholar 

  • Forsman A, Larsson M. Metabolism of haloperidol. Current Therapeutic Research 24: 567–568, 1978

    CAS  Google Scholar 

  • Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. Current Therapeutic Research 20: 319–336, 1976

    PubMed  CAS  Google Scholar 

  • Forsman A, Ohman R. Studies on serum protein binding of haloperidol. Current Therapeutic Research 21: 245–255, 1977

    PubMed  CAS  Google Scholar 

  • Forsman A, Ohman R. Interindividual variation of clinical response to haloperidol. In Obiols et al. (Eds) Biological psychiatry today, pp. 949–954, Elsevier/North-Holland Biomedical Press, Amsterdam, 1979

    Google Scholar 

  • Frantz AG. Catecholamines and the control of prolactin secretion in humans. In Zimmerman et al. (Eds) Progress in brain research, drug effects on neuroendocrine regulation, p. 311, Elsevier Press, London, 1973

    Chapter  Google Scholar 

  • Fuller AK, Tinige D, DeVane CL, Scott JA, Stewart RB. Haloperidol pharmacokinetics following gastric bypass surgery. Journal of Clinical Psychopharmacology 6: 376–378, 1986

    PubMed  CAS  Google Scholar 

  • Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML. Haloperidol red blood cell levels and clinical antipsychotic response. Journal of Clinical Psychopharmacology 4(3): 133–137, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gibaldi M, Perrier P. Pharmacokinetics: drugs and the pharmaceutical sciences, Vol. 15, pp. 83–84, Marcel Dekker Inc., New York, 1982

    Google Scholar 

  • Greendyke RM, Gulya A. Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin and phenobarbital. Journal of Clinical Psychiatry 49: 105–107, 1988

    PubMed  CAS  Google Scholar 

  • Greendyke RM, Kanter DR. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. Journal of Clinical Psychopharmacology 7: 178–182, 1987

    Article  PubMed  CAS  Google Scholar 

  • Groves JE. Prescribing long-acting neuroleptics. Drug Therapy 9: 106–111, 1979

    Google Scholar 

  • Groves JE, Mandel MR. The long-acting phenothiazines. Archives of General Psychiatry 32: 893–900, 1975

    Article  PubMed  CAS  Google Scholar 

  • Gruen PH, Sacher EJ, Langer G, Altman N, Leifer M, et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Archives of General Psychiatry 35: 108–116, 1978

    Article  PubMed  CAS  Google Scholar 

  • Hays SE, Poland RE, Rubin RT. Prolactin releasing potencies of antipsychotic and related nonantipsychotic compounds in female rats: relation to clinical potencies. Journal of Pharmacology and Experimental Therapeutics 214: 362–367, 1980

    PubMed  CAS  Google Scholar 

  • Heykants JJP, Gelders YG. Haloperidol decanoate: pharmacokinetics in dogs and man. In Burrows et al. (Eds) Biological psychiatry — recent studies (selected papers from the 13th CNIP Congress, Jerusalem), 1982, pp. 12–20, John Libby, London, 1984

    Google Scholar 

  • Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE. Haloperidol kinetics after oral and intravenous doses. Clinical Pharmacology and Therapeutics 33: 477–484, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hubbard JW, Ganes D, Midha KK. Prolonged pharmacologic activity of neuroleptic drugs. Archives of General Psychiatry 44: 99–100, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ishizaki T, Chiba K, Saito M, Kobayashi K, Lizuka R. The effects of neuroleptics on the pharmacokinetics of valproic acid in schizophrenic patients. Journal of Clinical Psychopharmacology 4: 254–261, 1984

    Article  PubMed  CAS  Google Scholar 

  • Itoh H, Yagi G, Ohtsuka N, Iwamura K, Ichikawa K. Serum level of haloperidol and its clinical significance. Progress in Neuropsychopharmacology and Biological Psychiatry 4: 171–183, 1980

    CAS  Google Scholar 

  • Jann MW, Chang WH, Davis CM, Chen TY, Deng HC, et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Research, in press, 1989b

    Google Scholar 

  • Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of depot antipsychotics. Clinical Pharmacokinetics 10: 315–333, 1985

    Article  PubMed  CAS  Google Scholar 

  • Jann MW, Ereshefsky L, Saklad SR, Richards AL. Haloperidol and reduced haloperidol plasma levels in schizophrenic patients. Drug Intelligence and Clinical Pharmacy 18: 507, 1984

    Google Scholar 

  • Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, et al. Effect of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology 5: 106–109, 1985

    Article  PubMed  CAS  Google Scholar 

  • Jann MW, Fidone GS, Hernandez JM, Amrung S, Davis CM. Clinical implication of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Research 24: 153–159, 1989c

    Article  Google Scholar 

  • Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenics. Psychopharmacology, in press, 1989a

    Google Scholar 

  • Jann MW, Ludden TM, Ereshefsky L, Saklad SR, Richards AL. Preliminary analysis of haloperidol population kinetics in schizophrenics. Clinical Pharmacology and Therapeutics 37: 203, 1985

    Google Scholar 

  • Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 90: 468–470, 1986

    Article  PubMed  CAS  Google Scholar 

  • Javaid JI, Pandey GN, Duslak B, Hu HY, Davis JM. Measurement of neuroleptic concentrations by GLC and radioreceptor assay. Communications in Psychopharmacology 4: 467–475, 1984

    Google Scholar 

  • Jorgensen A. Pharmacokinetic studies in volunteers of intravenous and oral cis(z)-flupentixol and intramuscular cis(z)-flupentixol decanoate in Viscoleo. European Journal of Clinical Pharmacology 18: 355–360, 1980

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen A, Gottfries CG. Pharmacokinetic studies on flupenthinol and flupenthixol decanoate in man using tritium labelled compounds. Psychopharmacology 27: 1–10, 1972

    Article  CAS  Google Scholar 

  • Kidron R, Averbuch I, Klein E, Belmaker R. Carbamazepine induced reduction in blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry 20: 199–228, 1985

    Article  Google Scholar 

  • Kirch DG, Bigelow LB, Wyatt RJ. The interpretation of plasma haloperidol concentrations. Archives of General Psychiatry 42: 838–839, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Kirch DG, Korpi ER, Danable D, Bigelow LB, Wyatt RJ. Acute dose and steady state haloperidol pharmacokinetics in schizophrenia. IV World Congress of Biological Psychiatry. Abstract, p. 339, 1985c

  • Kirch DG, Palmer M, Egan M, Freedman R. Electrophysiological interactions between haloperidol and reduced haloperidol and dopamine, norepinephrine and phencyclidine in rat brain. Neuropharmacology 24: 375–379, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Kogan MJ, Peirson D, Verebey K. Quantitative determination of haloperidol in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring 5: 485–489, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kolakowska T, Braddock L, Wiles D, Franklin M, Gelder M. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma response to haloperidol challenge. British Journal of Psychiatry 139: 400–412, 1981

    Article  PubMed  CAS  Google Scholar 

  • Korpi ER, Costakos DT, Wyatt RJ. Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration. Acta Pharmacological Toxicology 56: 94–98, 1985a

    Article  CAS  Google Scholar 

  • Korpi ER, Costakos DT, Wyatt RJ. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochemical Pharmacology 34: 2923–2927, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Korpi ER, Kleinman JE, Costakos DT, Linniola M, Wyatt RJ. Reduced haloperidol in the post-mortem brains of haloperidol treated patients. Psychiatry Research 11: 259–269, 1984c

    Article  PubMed  CAS  Google Scholar 

  • Korpi ER, Ko GN, Phelps BH, Wyatt RJ. Possible interference by the reduced haloperidol metabolite with the radioimmunoassay and radioreceptor assay of blood haloperidol. Journal of Clinical Psychopharmacology 4: 332–336, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Korpi ER, Phelps BH, Granger H, Chang WH, Linniola M, et al. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clinical Chemistry 29: 624–628, 1983

    PubMed  CAS  Google Scholar 

  • Korpi ER, Wyatt RJ. Reduced haloperidol: effects of striatal dopamine metabolism and conversion to haloperidol an the rat. Psychopharmacology 83: 34–37, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Kurland AA, Nagaraju A, Hanlon TE, Wilkinson EH, Ng KT. A comparison of dopamine receptor blocking assay with plasma levels of haloperidol in schizophrenic patients. Journal of Clinical Pharmacology 21: 42–47, 1981

    PubMed  CAS  Google Scholar 

  • Larsson M, Forsman A, Ohman R. A high performance liquid chromatographic method for the determination of haloperidol and reduced haloperidol in serum. Current Therapeutic Research 34: 99–1008, 1983

    Google Scholar 

  • Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. Journal of Clinical Psychopharmacology 8(3): 195–201, 1988

    Article  PubMed  CAS  Google Scholar 

  • Linniola M, Vuikari MM, Vaisanen K, Auvinen J. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry 137: 819–821, 1980

    Google Scholar 

  • Maas JW, Contreras SA, Seleshi E, Bowden CL. Dopamine metabolism and disposition in schizophrenic patients: studies using debrisoquin. Archives of General Psychiatry 45: 553–559, 1988

    Article  PubMed  CAS  Google Scholar 

  • Magliozzi JR, Hillister LE. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. Journal of Clinical Psychiatry 46: 20–21, 1985

    PubMed  CAS  Google Scholar 

  • Magliozzi JR, Hollister LE, Arnold KV, Earle GM. Relationship of serum haloperidol levels in clinical response in schizophrenic patients. American Journal of Psychiatry 138(3): 365–367, 1981

    PubMed  CAS  Google Scholar 

  • Mailman ARB, Pierce JP, Crofton KM, Petitto J, DeHaven DL, et al. Thioridazine and the neuroleptic radioreceptor assay. Biological Psychiatry 19: 833–847, 1984

    PubMed  CAS  Google Scholar 

  • Marcucci F, Mussini E, Airoldi L, Fanelli R, Frigerio A, et al. Analytical and pharmacokinetic studies on butyrophenones. Clinica Chimica Acta 34: 321–332, 1971

    Article  CAS  Google Scholar 

  • Mason AS, Granacher RP. Basic principles of rapid neuroleptization. Diseases of the Nervous System 37: 547–551, 1976

    PubMed  CAS  Google Scholar 

  • Matsunaga Y, Nambu K, Oh-e Y, Miyazaki Hashimoto M. Excretion and metabolism of intramuscularly administered (14C)-haloperidol decanoate in rats. Arzneimittel-Forschung 36: 453–456, 1986

    PubMed  CAS  Google Scholar 

  • Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81: 354–356, 1983

    Article  PubMed  CAS  Google Scholar 

  • Meco G, Casacchia M, Attenni M, Iatrate A, Castellana F, et al. Haloperidol decanoate in schizophreniform disorders. Acta Psychiatrica Belgica 83: 57–68, 1983

    PubMed  CAS  Google Scholar 

  • Meitzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry 33: 279–286, 1976

    Article  Google Scholar 

  • Midha KK, Cooper JK, Hawes EM, Hubbard JW, Korchinski Ed, et al. An ultrasensitive method for the measurement of haloperidol and reduced haloperidol in plasma by high-performance liquid chromatography with coulometric detection. Therapeutic Drug Monitoring 10: 177–183, 1988

    Article  PubMed  CAS  Google Scholar 

  • Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G. Interconversion between haloperidol and reduced haloperidol. Journal of Clinical Psychopharmacology 7: 362–363, 1987

    Article  PubMed  CAS  Google Scholar 

  • Miller DD, Hershey LA, Duffy JP, Abernethy DR, Greenblatt DJ. Serum haloperidol concentrations and clinical response in acute psychosis. Journal of Clinical Psychopharmacology 4(6): 305–310, 1984

    Article  PubMed  CAS  Google Scholar 

  • Miller R, De Vane CL. Measurement of haloperidol and reduced haloperidol in human plasma using reversed plasma high performance liquid chromatography. Journal of Chromatography 374: 405–408, 1986

    Article  PubMed  CAS  Google Scholar 

  • Miyazaki K, Arita T. High performance chromatographic determination of haloperidol in plasma. Journal of Chromatography 223: 449–452, 1981

    Article  PubMed  CAS  Google Scholar 

  • Moller HJ, Kissling W, Lang C, Coerr P, Pirkle KM, et al. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. American Journal of Psychiatry 139: 1571–1575, 1982

    PubMed  CAS  Google Scholar 

  • Morselli PL, Bianchetti G, Dugas M. Haloperidol plasma level monitoring in neuropsychiatric patients. Therapeutic Drug Monitoring 4: 51–58, 1982

    Article  PubMed  CAS  Google Scholar 

  • Morselli PL, Bianchetti G, Dugas M. Therapeutic drug monitoring of psychotropic drugs in children. Pediatric Pharmacology 3: 149–156, 1983

    PubMed  CAS  Google Scholar 

  • Morselli PL, Bianchetti G, Durand G, LeHeuzey MF, Zarifian E, et al. Haloperidol plasma level monitoring in pediatric patients. Therapeutic Drug Monitoring 1: 35–46, 1979

    Article  PubMed  CAS  Google Scholar 

  • Nathan RS, Perel J, Stiller R, McCarthy T, Curran S. Chronopharmacology of haloperidol in schizophrenic patients. Annual Review of Chronopharmacology 3: 455–458, 1986

    Google Scholar 

  • Nayak RK, Nair NPV, Doose DR, McCarthy LR, Desiraju RK. Pharmacokinetics of haloperidol and haloperidol decanoate in schizophrenic patients. Clinical Pharmacology and Therapeutics 37: 217, 1985

    Google Scholar 

  • Neborsky R, Janowsky D, Munson E, Hornbeck C, Depry D. Behavioural prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry 43: 157–158, 1982b

    PubMed  CAS  Google Scholar 

  • Neborsky R, Janowsky DS, Perel J, Munson E, Depry D. Haloperidol plasma/red blood cell ratios and clinical efficacy. Psychopharmacology Bulletin 18(4): 17–20, 1982a

    PubMed  CAS  Google Scholar 

  • Neborsky R, Janowsky DS, Perel J, Munson E, Depry D. Plasma/ RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry 45: 10–13, 1984

    PubMed  CAS  Google Scholar 

  • Nemes ZC, Volavka J, Cooper TB, O’Donnell J, Jaeger J. Lithium and haloperidol. Biological Psychiatry 21: 568–569, 1986

    Article  PubMed  CAS  Google Scholar 

  • Nemes ZC, Volavka J, Lajtha A, Cooper TB, Sershen H. Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs. Psychiatry Research 20: 313–316, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ohman R, Axelsson R. Relationship between prolactin response and antipsychotic effect of thioridazine in psychiatric patients. European Journal of Clinical Pharmacology 14: 111–116, 1978

    Article  PubMed  CAS  Google Scholar 

  • Pape BE. Isolation and identification of a metabolite of haloperidol. Journal of Analytical Toxicology 5: 113–117, 1981

    PubMed  CAS  Google Scholar 

  • Parent M, Toussaint CH, Driesens F, Gelders YG. Pharmacocinétique du decanoate d’haloperidol chez le psychotique. Acta Psychiatrica Belgica 81: 399–406, 1981

    PubMed  CAS  Google Scholar 

  • Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry 43: 669–676, 1986

    Article  PubMed  CAS  Google Scholar 

  • Post RM, Goodwin FK. Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190: 488–489, 1975

    Article  PubMed  CAS  Google Scholar 

  • Potkin SG, Shen Y, Pardes H, Phelps B, Zhou D, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Research 12: 167–172, 1984

    Article  PubMed  CAS  Google Scholar 

  • Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, et al. Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacology Bulletin 21(1): 59–61, 1985

    PubMed  CAS  Google Scholar 

  • Rao VA, Bishop M, Coppen A. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. British Journal of Psychiatry 137: 518–521, 1980

    Article  PubMed  CAS  Google Scholar 

  • Reyntijens AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aerts TJL. Pharmacokinetics of haloperidol decanoate. International Pharmacopsychiatry 17: 238–246, 1982

    Google Scholar 

  • Richards MF, Actis Dato AC, Zelascki NM, Balbo EA, Canero EC. Monthly haloperidol decanoate substitute for daily neuroleptics in psychotic patients. Current Therapeutic Research 30: 586–589, 1983

    Google Scholar 

  • Rimon R, Averbuch, Rozick P, Fijman-Danilovich L, Kara T, et al. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 73: 197–199, 1981

    Article  PubMed  CAS  Google Scholar 

  • Rowell FJ, Hui SM, Fairbairn AF, Eccleston D. Total and free serum haloperidol levels in schizophrenic patients and’ the effect of age, thioridazine and fatty acid on haloperidol-serum protein binding in vitro. British Journal of Clinical Pharmacology 11: 377–382, 1981

    Article  PubMed  CAS  Google Scholar 

  • Rubin RT, Forsman A, Heykants J, Ohman R, Tower B, et al. Serum haloperidol determinations in psychiatric patients: comparison of methods and correlation with serum prolactin level. Archives of General Psychiatry 37: 1069–74, 1980

    Article  PubMed  CAS  Google Scholar 

  • Sachar EJ, Gruen PH, Altman N, Halpern F, Fantz AG. Use of neuroendocrine techniques in psychopharmacological research. In Sachar (Ed.) Hormones, behavior and psychopharmacology, pp. 161–176, Raven, New York, 1976

    Google Scholar 

  • Sangiovanni F, Taylor MA, Abrams R, Gaztanaga P. Rapid control of psychotic excitement states with intramuscular haloperidol. American Journal of Psychiatry 130: 115–116, 1973

    Google Scholar 

  • Schaeffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. Journal of Clinical Psychopharmacology 2: 274–276, 1982

    Google Scholar 

  • Sherman MA, Linthicum DS, Bolger MB. Haloperidol binding to monoclonal antibodies: conformational analysis and relationship to D-2 receptor binding. Journal of Pharmacology and Experimental Therapeutics 29: 589–598, 1987

    Google Scholar 

  • Shostak M, Perel JM, Stiller RL, Wyman W, Curran S. Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity? Journal of Clinical Psychopharmacology 7(6): 394–400, 1987

    Article  PubMed  CAS  Google Scholar 

  • Shvartsburd A, Dekirmejian H, Smith R. Blood levels of haloperidol in schizophrenic patients. Journal of Clinical Psychopharmacology 3: 7–12, 1983

    Article  PubMed  CAS  Google Scholar 

  • Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of Psychiatric Research 18(3): 255–268, 1984

    Article  PubMed  CAS  Google Scholar 

  • Smith RC. Letter to the editor. Archives of General Psychiatry 42: 835–837, 1985

    Article  Google Scholar 

  • Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacology Bulletin 21(1): 52–58, 1985

    PubMed  CAS  Google Scholar 

  • Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, et al. Haloperidol plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical versus radioreceptor plasma level assays. Archives of General Psychiatry 41: 1044–1049, 1984

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Crayton F, Dekirmenjian H, Klass D, Davis JM. Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Archives of General Psychiatry 36: 579–583, 1979

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, et al. RBC and plasma haloperidol and clinical response in schizophrenia. American Journal of Psychiatry 139: 1054–1056, 1982

    PubMed  CAS  Google Scholar 

  • Stafford JE, Jackson LS, Forrest TJ, Barrow A, Plamer RF. Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. Journal of Pharmacological Methods 6: 261–279, 1981

    Article  PubMed  CAS  Google Scholar 

  • Sussman N. Treatment of anxiety with buspirone. Psychiatric Annals 17: 114–117, 1987

    Google Scholar 

  • Suzuki H, Minaki Y, Iwaisaki M, Sekine Y, Kagemoto A, et al. Determination of haloperidol in human serum by radioimmunoassay. Journal of Pharmaceutical Dynamics 3: 250–257, 1980

    Article  CAS  Google Scholar 

  • Szczepanik-Van Leeuwen P. Improved gas chromatographic mass spectrometric assay for haloperidol utilizing ammonia chemical ionization and selected in monitoring. Journal of Chromatography 339: 321–330, 1985

    Article  PubMed  CAS  Google Scholar 

  • Takeda M, Nishinuma K, Yamashita S, Matsubayashi T, Tanino S, et al. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. Clinical Neuropharmacology 9: 386–397, 1986

    Article  PubMed  CAS  Google Scholar 

  • Van Putten TV, Marder SR, May PRA, Poland RE, O’Brian RP. Plasma levels of haloperidol and clinical response. Psychopharmacology Bulletin 21(1): 69–72, 1985

    PubMed  Google Scholar 

  • Viukari M, Salo H, Lamminsivu U, Gordin A. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatrica Scandinavica 65: 301–308, 1982

    Article  PubMed  CAS  Google Scholar 

  • Volavka J, Cooper TB. Review of haloperidol blood levels and clinical response: looking through the window. Journal of Clinical Psychopharmacology 7: 25–30, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wurzburger RJ, Miller RL, Marcum EA, Colburn WA, Spector S. A new radioimmunoassay for haloperidol: direct measurement of serum and striatal concentrations. Journal of Pharmacology and Experimental Therapeutics 217: 757–763, 1981

    PubMed  CAS  Google Scholar 

  • Yamazumi S, Miura S. Haloperidol concentrations in saliva and serum: determination by the radioimmunoassay method. International Pharmacopsychiatry 16: 174–183, 1981

    PubMed  CAS  Google Scholar 

  • Young D, Eddington ND. Pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs. Clinical Pharmacology and Therapeutics 43: 177, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA

    J. S. Froemming, Y. W. Francis Lam,  M. W. Jann & C. M. Davis

  2. Division of Clinical Pharmacy, The University of Texas Health Science Center at San Antonio and College of Pharmacy, The University of Texas at Austin, Texas, USA

    J. S. Froemming, Y. W. Francis Lam,  M. W. Jann & C. M. Davis

  3. Analytical Neurochemistry, The University of Texas Mental Science Institute, Houston, Texas, USA

    J. S. Froemming, Y. W. Francis Lam,  M. W. Jann & C. M. Davis

Authors
  1. J. S. Froemming
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. W. Francis Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. W. Jann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. M. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Froemming, J.S., Lam, Y.W.F., Jann, M.W. et al. Pharmacokinetics of Haloperidol. Clin-Pharmacokinet 17, 396–423 (1989). https://doi.org/10.2165/00003088-198917060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198917060-00004

Keywords

Search

Navigation